The HRs in the analyses of OS favored anti-PD-1/PD-L1 antibodies in the following subgroups: patients in the US/Canada, patients who were white, patients receiving second-line therapy, age <75 years, both sexes, ECOG score of 0–1, history of tobacco use, squamous or adenocarcinoma NSCLC, no central nervous system (CNS) metastases, EGFR mutation–negative status, KRAS mutation–positive status, and ALK mutation–negative status (Figure 7). This evidence concerns the gene ALK and non-small cell lung carcinoma.